anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An immunologic method has been devised enabling diagnosis of patients with cystic fibrosis, as well as asymptomatic carriers of the cystic fibrosis gene. Mono-specific antibody to Cystic Fibrosis Protein (CFP) is inserted into a first position on an electrophoresis plate. A body fluid from the subject to be tested is placed into a second position on the plate. An electrical potential is imposed across the positions with the anode being adjacent to the section containing the serum and the cathode being adjacent to the section containing the antibody. The presence of Cystic Fibrosis Protein is indicated by one or more precipitation zones forming where the body fluid proteins meet the antibody due to movement induced by an applied electrical potential. The relative position of the precipitation zone between the first and second positions, or the area of the precipitation zone, indicates a concentration of the Cystic Fibrosis Protein. Methods for producing the purified Cystic Fibrosis Protein antibody and for purifying the Cystic Fibrosis Protein itself are also disclosed.
Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring from a trained interventionist. Participants will be asked to weigh daily on a digital scale, which will be provided.
Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Group 3 will include patients who have previously received vaccine and oral β glucanglucan. Patients in this group will not be randomized using the MSK CRDB system. They will be treated as patients in Group 1 and receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination . They will not be eligible for primary endpoint.
The invention relates to sgRNA of a targeted TLC region and application thereof, and belongs to the technical field of genetic engineering. The targeting sequence of the sgRNA comprises nucleotide sequences shown in SEQ ID NO. 1-SEQ ID NO. 29; the sgRNA sequence has the advantages that the sgRNA sequence can accurately identify TLC regions, so that efficient chromosome fusion is completed. Chromosome fusion can be directly induced by transfecting cells with the sgrnas of the present invention. Compared with the related art, the method has the advantages of greatly improving the probability of chromosome fusion and simplifying the flow.
Cartilage, a flexible and smooth connective tissue that envelops the surfaces of synovial joints, relies on chondrocytes for extracellular matrix (ECM) production and the maintenance of its structural and functional integrity. Melatonin (MT), renowned for its anti-inflammatory and antioxidant properties, holds the potential to modulate cartilage regeneration and degradation. Therefore, the present study was devoted to elucidating the mechanism of MT on chondrocytes. The in vivo experiment consisted of three groups: Sham (only the skin tissue was incised), Model (using the anterior cruciate ligament transection (ACLT) method), and MT (30 mg/kg), with sample extraction following 12 weeks of administration. Pathological alterations in articular cartilage, synovium, and subchondral bone were evaluated using Safranin O-fast green staining. Immunohistochemistry (ICH) analysis was employed to assess the expression of matrix degradation-related markers. The levels of serum cytokines were quantified via Enzyme-linked immunosorbent assay (ELISA) assays. In in vitro experiments, primary chondrocytes were divided into Control, Model, MT, negative control, and inhibitor groups. Western blotting (WB) and Quantitative RT-PCR (q-PCR) were used to detect Silent information regulator transcript-1 (SIRT1)/Nuclear factor kappa-B (NF-κB)/Nuclear factor erythroid-2-related factor 2 (Nrf2)/Transforming growth factor-beta (TGF-β)/Bone morphogenetic proteins (BMPs)-related indicators. Immunofluorescence (IF) analysis was employed to examine the status of type II collagen (COL2A1), SIRT1, phosphorylated NF-κB p65 (p-p65), and phosphorylated mothers against decapentaplegic homolog 2 (p-Smad2). In vivo results revealed that the MT group exhibited a relatively smooth cartilage surface, modest chondrocyte loss, mild synovial hyperplasia, and increased subchondral bone thickness. ICH results showed that MT downregulated the expression of components related to matrix degradation. ELISA results showed that MT reduced serum inflammatory cytokine levels. In vitro experiments confirmed that MT upregulated the expression of SIRT1/Nrf2/TGF-β/BMPs while inhibiting the NF-κB pathway and matrix degradation-related components. The introduction of the SIRT1 inhibitor Selisistat (EX527) reversed the effects of MT. Together, these findings suggest that MT has the potential to ameliorate inflammation, inhibit the release of matrix-degrading enzymes, and improve the cartilage condition. This study provides a new theoretical basis for understanding the role of MT in decelerating cartilage degradation and promoting chondrocyte repair in in vivo and in vitro cultured chondrocytes.
There is compelling evidence that a comprehensive CR program comprising the delivery of lifestyle modifying education will reduce mortality, morbidity and improve quality of life in patients following myocardial infarction, unstable angina, angioplasty or coronary artery bypass. However less than 20% of eligible patients participate in CRSP programs. This study will look at a method of potentially improving enrollment and adherence to a CRSP program. Patients will be randomized into two groups. One group will complete a survey and view a videotape introducing the concept of a CRSP program. The second group will be requested to complete a survey only, but will not be exposed to the videotape. It is expected that the patients who view the videotape will be more likely to express intent to participate in CRSP versus those patients who do not view the videotape.
In this double-blind, crossover study, the investigators are proposing to evaluate galantamine's effects on the subjective nicotine effects and the severity of tobacco withdrawal symptoms. Twenty four male and female smokers will first have two 4-day treatment periods, in which subjects will be randomized to galantamine (8 mg/day) or placebo. These treatment periods will be separated by a 3 to 14 day washout period. This range of washout period, while minimizing carryover medication effects between treatments, will provide flexibility for subjects to comply with study procedures. During study participation, subjects will be instructed to continue to smoke as usual during the study except the 2.5 days of smoking abstinence before each test session. Starting at 10 p.m. on Day 1 of each treatment period, subjects will refrain from smoking for approximately 2.5 days, until the test session on Day 4. Subjects will have twice daily outpatient visits during the first 3 days and a test session on day 4. During the outpatient visits, study medication will be administered and tobacco withdrawal symptoms and compliance with smoking abstinence will be monitored. On Day 4 of each treatment phase subjects will have a test session, where they will receive saline or 1.0 mg/70 kg of nicotine intravenously in a random, double-blind manner. The sequence of nicotine treatments will be counterbalanced among subjects such that equal number of subjects will receive saline first or nicotine first. Following each saline and nicotine administration, physiological, subjective and cognitive measurements will be obtained.

Currently 12 subjects completed this protocol. This study is in data analysis. (April 2011)
PURPOSE:To obtain calcium phosphate ceramics which is made porous only on the surface to have the porous surface of high strength with a simple stage by treating the calcium phosphate ceramics consisting of a mixture composed of hydroxyapatite and tricalcium phosphate with an acid soln. CONSTITUTION:The calcium phosphate ceramics consisting of the mixture composed of the hydroxyapatite and tricalcium phosphate is treated with the acid soln. to elute the tricalcium phosphate selectively, by which the porous surface is obtd. The Ca/P ratio of the above-mentioned mixture is preferably 1.53-1.64. Calcination in the production of the calcium phosphate ceramics is preferably executed at 700-1,400 deg.C. For example, hydrochloric acid, sulfuric acid, nitric acid, etc., are usable as the above-mentioned acid soln. The pH of the acid soln. is preferably 1-5.5 and the treating time is 1sec-24hr.
Subjects will wear Touchpoints devices on both ankles daily for 10 days. The devices will be worn \~1 hour before bedtime and through the night. They will be removed upon waking in the morning.
Acute aortic syndromes (AAS) result from an organic lesion of the aortic wall. The various symptoms of AAS, mainly the acute chest pain, leads to a breakdown of the intima or the media of the aorta. This syndrome is made of three entities : aortic dissection (DA), intra-mural hematoma (HIM) and penetrating atherosclerotic ulcer (PAU). Surgery is a complex emergency treatment of choice. Patients suffering from these pathologies die mainly from hemorrhagic shock due to haemostasis disorders, which requires massive transfusion. The existence of AAS coagulopathy has been reported, related to blood contact with the walls of the non-endothelialized false lumens. It is likely that endothelial dysfunction generated by vascular lesions may largely contribute to the development of coagulopathy, such as described in trauma-induced coagulopathy. This endotheliopathy of the AAS has never been evaluated. The coagulopathy of AAS and more specifically the endotheliopathy are poorly described and therefore have no standardized treatment.

The main objective of this study is to describe the coagulopathy and more specifically the endotheliopathy of AAS, in particular assessing coagulation disorders, hyperactivation of fibrinolysis, quantitative or functional platelets disorder and endotheliopathy. The secondary objective is to determine the factors associated with this coagulopathy. This includes 1 / assessment of potential risk factors for coagulopathy, 2 / the prognosis of coagulopathy by assessing the relationship between coagulopathy and transfusion requirements and mortality.
Systems and methods are provided for preparing a regimen for improving a subject's ability to manage a psychotic disorder or condition. The method includes presenting a first digital reality scene having an interactive digital chart and a bin. The bin includes a plurality of nodes. Each node corresponds to a respective category of the plurality of categories and a plurality of suggested experiences associated with the respective category. Each suggested experience is associated with a unique digital reality scene that is different from the first digital reality scene that presents challenges represented by the respective category and/or the respective suggested experience. Each node is also associated with at least one respective gate criterion. The method also includes detecting selection of a node and placing the node on the graph, thereby providing access to a corresponding plurality of suggested experiences associated with the respective category.
Use of highly active antiretroviral therapy (HAART) has resulted in significant reductions in morbidity and mortality among HIV infected people. However, significant adverse effects, including dyslipidemia, have been associated with HAART. Dyslipidemia may cause elevations in serum total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride concentrations, as well as a decrease in high-density lipoprotein (HDL) concentrations. Dyslipidemia is of particular concern for patients receiving HAART because the condition is associated with increased risk for cardiovascular events. TDF is an antiretroviral that has exhibited favorable lipid effects in several studies in HIV infected people, but the mechanism for the observed lipid-lowering effect of TDF is unknown. This study will evaluate the efficacy of TDF on lowering non-HDL in HIV infected adults currently on stable HAART. HAART itself will not be provided by this study.

This study will last 32 weeks. Participants will be randomly assigned to one of two study arms. Arm A participants will receive 12 weeks of TDF daily, 4 weeks of no TDF, 12 weeks of placebo daily, then 4 weeks of no TDF. Arm B participants will receive 12 weeks of placebo daily, 4 weeks of no TDF, 12 weeks of TDF daily, then 4 weeks of no TDF. Participants will continue to take their currently prescribed stable HAART regimen for the duration of the study. There will be 13 study visits over the 32 weeks of the study. Clinical assessments will occur at all visits; blood and urine collection will occur at most visits.
The present invention discloses a compound ibuprofen medical patch for treating scapulobumeral periarthritis. The medical patch is of a lunes-shaped three-layer structure, which comprises an anti-stick film layer (1), an ointment layer (2), and a carrier layer (3). The ointment layer (2) comprises 1.0-1.5 parts of ibuprofen by weight, a Chinese medicine ingredient, and a matrix. The bulk pharmaceutical chemicals of the Chinese medicine ingredient are as follows by weight: 35-45 parts of clematis root, 20-30 parts of levisticum, 35-45 parts of speranskia herb, 25-35 parts of safflower, 25-35 parts of Chinese angelica, 2-5 parts of pangolin, 35-45 parts of ramulus mori, and 30-40 parts of monkshood. The components of the matrix are as follows by weight: 5-10 parts of yellow lead, 7-12 parts of Vaseline and 1-3 parts of acrylic resin. According to the technical scheme of the invention, the compound ibuprofen medical patch is of the lunes-shaped three-layer structure, thus conforming to the physical features of human bodies. Medical ingredients can be released slowly and permanently, so that the purpose of treating both symptoms and root causes is realized. The scapulobumeral periarthritis can be thoroughly cured. The compound ibuprofen medical patch is high in utilization rate of medical effective compositions, simple in process, good in reproducibility and easy in industrial production.
Ultrasound shear wave elastography (SWE) is a noninvasive approach for evaluating mechanical properties of soft tissues. In SWE either group velocity measured in the time-domain or phase velocity measured in the frequency-domain can be reported. Frequency-domain methods have the advantage over time-domain methods in providing a response for a specific frequency, while time-domain methods average the wave velocity over the entire frequency band. Current frequency-domain approaches struggle to reconstruct SWE images over full frequency bandwidth. This is especially important in the case of viscoelastic tissues, where tissue viscoelasticity is often studied by analyzing the shear wave phase velocity dispersion. For characterizing cancerous lesions, it has been shown that considerable biases can occur with group velocity-based measurements. However, using phase velocities at higher frequencies can provide more accurate evaluations. In this paper, we propose a new method called Ultrasound Shear Elastography with Expanded Bandwidth (USEWEB) used for two-dimensional (2D) shear wave phase velocity imaging. We tested the USEWEB method on data from homogeneous tissue-mimicking liver fibrosis phantoms, custom-made viscoelastic phantom measurements, phantoms with cylindrical inclusions experiments, and in vivo renal transplants scanned with a clinical scanner. We compared results from the USEWEB method with a Local Phase Velocity Imaging (LPVI) approach over a wide frequency range, i.e., up to 200-2000 Hz. Tests carried out revealed that the USEWEB approach provides 2D phase velocity images with a coefficient of variation below 5% over a wider frequency band for smaller processing window size in comparison to LPVI, especially in viscoelastic materials. In addition, USEWEB can produce correct phase velocity images for much higher frequencies, up to 1800 Hz, compared to LPVI, which can be used to characterize viscoelastic materials and elastic inclusions.
Dehydration and malnutrition are common in infants with severe epidermolysis bullosa (EB), but their nutritional needs have been poorly studied. The principal aim was to assess the nutritional status, fluid and electrolyte balance, and nutritional intake of newborns with EB during the first month of life and estimate their needs during this period. This was a retrospective study over an eight-year period. Inclusion criteria were neonates with confirmed EB admitted to our neonatal referral unit during the first month of life. Exclusion criteria were hospitalisations <7 days. Twenty-seven patients with EB (mean [min-max] gestational age = 39 weeks [33; 41]; birth weight = 2986 g [1982; 4150]), were included. Four patients (15%) had hyponatraemia < 135 mmol/L at admission (age at admission = 4.8 days +/- 2.6 [2; 7]). Sixteen patients (59%) had a sodium deficit -requiring fluid and sodium intake well above recommendations from the World Health Organisation (WHO). The risk of hyponatraemia was significantly higher in infants with the greatest body surface area affected but did not appear to be related to EB subtype. Caloric and protein intake were well above the WHO's recommendations, preventing acquired growth restriction. The rate of sodium deficit in neonates with EB is high and related to the significance of skin exudate. The administration of nutrient intake greater than that recommended helps to prevent acquired growth restriction. We propose recommendations for nutritional intake and monitoring in neonates with EB in the first month of life.
While wait-listed, participants will receive one push notification each week thanking them for participation, informing them that they will receive messages in the near future or reminding them of the length of the study. Telephone-based assessments are completed at baseline, 1- and 2-month follow up. Push notifications are delivered by study's mobile app downloaded to participants' own Smartphone.
Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. 

These doses are both approximately 4 times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day. 

There was no evidence of a mutagenic potential of metformin in the following in vitro tests: Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also negative. 

  


Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.
Combining two or more related homoeologous genomes in a single nucleus, newly formed allopolyploids must rapidly adapt meiosis to restore balanced chromosome segregation, production of euploid gametes and fertility. The poor fertility of such neo-allopolyploids thus strongly selects for the limitation or avoidance of genetic crossover formation between homoeologous chromosomes. In this study, we have reproduced the interspecific hybridization between Arabidopsis thaliana and Arabidopsis arenosa leading to the allotetraploid Arabidopsis suecica and have characterized the first allopolyploid meioses. First-generation neo-allopolyploid siblings vary considerably in fertility, meiotic behavior and levels of homoeologous recombination. We show that centromere dynamics at early meiosis is altered in synthetic neo-allopolyploids compared with evolved A. suecica, with a significant increase in homoeologous centromere interactions at zygotene. At metaphase I, the presence of multivalents involving homoeologous chromosomes confirms that homoeologous recombination occurs in the first-generation synthetic allopolyploid plants and this is associated with a significant reduction in homologous recombination, compared to evolved A. suecica. Together, these data strongly suggest that the fidelity of recombination partner choice, likely during the DNA invasion step, is strongly impaired during the first meiosis of neo-allopolyploids and requires subsequent adaptation.
Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
Washing and cleaning agents based on soap or synthetic detergents, and suitable for use on human skin and hair, contain as an additive a reaction product derived from (I) a polybasic organic aliphatic acid whose alkaline earth metal salt is readily soluble in water, and (II) a fatty compound selected from fatty acid amides, fatty acid alkylolamides, and C12- 22 alkyl or alkenyl ethers of di- and tri-alkylolamides. Suitable additives are the reaction products formed between (a) maleic acid and diethanolamine mono-oleyl ether, (b) succinic acid and stearide, (c) citric acid and triethanolamine dioleyl ether, (d) nitriloacetic acid or EDTA and triethanolamine di-stearyl ether. Typical compositions are based on alkali metal soaps; fatty alkyl sulphates (e.g. triethanolamine coconut alcohol sulphate) or mixtures thereof with oxyethylated fatty alkyl sulphates or fatty acid methyl taurides; or fatty alcohol ether sulphates, e.g. coconut-myristyl triethenoxy alcohol sulphates.  The compositions may also contain lanolin, and may be produced in the form of liquids, pastes or solids, e.g. bars, needles, flakes, or beads.
The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG- VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Thl type. Antigens attached to CpG-loaded VLPs may therefore be ....sim. ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.